Medpace (MEDP) to Announce Earnings on Wednesday

Medpace (NASDAQ:MEDP) is expected to be announcing its Q2 2026 results after the market closes on Wednesday, July 22nd. Analysts expect Medpace to post earnings of $3.98 per share and revenue of $689.5340 million for the quarter. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 23, 2026 at 9:00 AM ET.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.67 earnings per share. On average, analysts expect Medpace to post $17 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Medpace Stock Performance

NASDAQ MEDP opened at $527.93 on Tuesday. Medpace has a 1 year low of $306.70 and a 1 year high of $628.92. The business’s fifty day moving average is $480.31 and its two-hundred day moving average is $493.94. The stock has a market capitalization of $15.08 billion, a P/E ratio of 33.18, a P/E/G ratio of 2.69 and a beta of 1.15.

Wall Street Analysts Forecast Growth

MEDP has been the topic of a number of recent research reports. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and lifted their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Barclays reduced their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Robert W. Baird reissued a “neutral” rating and issued a $547.00 price target (up from $477.00) on shares of Medpace in a research note on Wednesday, July 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Finally, Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Two equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $469.50.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MEDP. Mcguire Capital Advisors Inc. bought a new position in Medpace during the fourth quarter valued at approximately $66,000. Axxcess Wealth Management LLC grew its holdings in Medpace by 503.7% in the 4th quarter. Axxcess Wealth Management LLC now owns 4,063 shares of the company’s stock valued at $2,282,000 after buying an additional 3,390 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Medpace by 26.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 28,064 shares of the company’s stock worth $15,762,000 after buying an additional 5,840 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in shares of Medpace during the fourth quarter worth approximately $281,000. Finally, Fuller & Thaler Asset Management Inc. boosted its position in shares of Medpace by 5.3% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 76,877 shares of the company’s stock valued at $43,178,000 after acquiring an additional 3,847 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.